Blockchain Registration Transaction Record

NanoViricides Advances NV-387 for Measles Amid Rising Cases

NanoViricides updates on NV-387 measles treatment, advancing to Phase II trials with FDA designations. Learn about the broad-spectrum antiviral's potential.

The resurgence of measles, a highly contagious and potentially fatal disease, underscores an urgent need for effective treatments. NanoViricides' NV-387, with its promising preclinical data and FDA designations, could become a crucial therapeutic option, especially for pediatric populations. If successful, it would address a significant public health gap, as current measles management relies primarily on supportive care and vaccination. Moreover, the potential Priority Review Voucher offers a financial incentive that could accelerate the drug's development and approval, benefiting patients and investors alike.